Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel

被引：3

作者：

Nishihara-Kato, Fuyumi ^{[1
]}

Imai, Hisao ^{[1
,2
,14
]}

Tsuda, Takeshi ^{[3
]}

Wasamoto, Satoshi ^{[4
]}

Nagai, Yoshiaki ^{[5
]}

Kishikawa, Takayuki ^{[6
]}

Miura, Yosuke ^{[7
]}

Ono, Akihiro ^{[8
]}

Yamada, Yutaka ^{[9
]}

Masubuchi, Ken ^{[2
]}

Osaki, Takashi ^{[10
]}

Nakagawa, Junichi ^{[11
]}

Umeda, Yukihiro ^{[12
]}

Minemura, Hiroyuki ^{[13
]}

Kozu, Yuki ^{[4
]}

Taniguchi, Hirokazu ^{[3
]}

Ohta, Hiromitsu ^{[5
]}

Kaira, Kyoichi ^{[1
]}

Kagamu, Hiroshi ^{[1
]}

机构：

[1] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka, Saitama, Japan

[2] Gunma Prefectural Canc Ctr, Div Resp Med, Ota, Gunma, Japan

[3] Toyama Prefectural Cent Hosp, Div Resp Med, Toyama, Toyama, Japan

[4] Saku Cent Hosp Adv Care Ctr, Div Resp Med, Saku, Nagano, Japan

[5] Jichi Med Univ, Saitama Med Ctr, Dept Resp Med, Saitama, Saitama, Japan

[6] Tochigi Canc Ctr, Div Thorac Oncol, Utsunomiya, Tochigi, Japan

[7] Gunma Univ Hosp, Integrat Ctr Internal Med, Div Allergy & Resp Med, Maebashi, Gunma, Japan

[8] Kiryu Kosei Gen Hosp, Div Internal Med, Kiryu, Gunma, Japan

[9] Ibaraki Cent Hosp, Div Resp Med, Kasama, Ibaraki, Japan

[10] Natl Hosp Org Shibukawa Med Ctr, Div Resp Med, Shibukawa, Gunma, Japan

[11] Natl Hosp Org Takasaki Gen Med Ctr, Div Resp Med, Takasaki, Gunma, Japan

[12] Univ Fukui, Fac Med Sci, Dept Internal Med 3, Eiheiji, Fukui, Japan

[13] Fukushima Med Univ, Dept Pulm Med, Fukushima, Japan

[14] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, 1397-1 Yamane, Hidaka City, Saitama 3501298, Japan

来源：

ONCOLOGY | 2024年 / 102卷 / 01期

关键词：

TO-LYMPHOCYTE RATIO; BODY-MASS INDEX; CLINICAL UTILITY; TREATED PATIENTS; SCORE GPS; INFLAMMATION; NEUTROPHIL; CHEMOTHERAPY; SURVIVAL; OUTCOMES;

D O I：

10.1159/000533604

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Pembrolizumab (Pemb) therapy in conjunction with carboplatin and paclitaxel (PTX)/nab-PTX has been efficacious in treating non-small-cell lung cancer (NSCLC). However, the response predictors of this combination therapy (Pemb-combination) remain undetermined. We aimed to evaluate whether Glasgow prognostic score (GPS), neutrophil-to-lymphocyte ratio (NLR), body mass index (BMI), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index (PNI) are potential factors in prognosticating the response to Pemb-combination therapy in advanced NSCLC patients. Methods: We retrospectively recruited 144 NSCLC patients receiving first-line treatment with Pemb-combination therapy from 13 institutions between December 1, 2018, and December 31, 2020. GPS, NLR, BMI, PLR, and PNI were assessed for their efficacy as prognostic indicators. Cox proportional hazard models and the Kaplan-Meier method were used to compare the progression-free survival (PFS) and overall survival (OS) of the patients.Results: The treatment exhibited a response rate of 63.1% (95% confidence interval [CI]: 55.0-70.6%). Following Pemb-combination administration, the median PFS and OS were 7.3 (95% CI: 5.3-9.4) and 16.5 (95% CI: 13.9-22.1) months, respectively. Contrary to PNI, NLR, GPS, BMI, and PLR did not display substantially different PFS in univariate analysis. However, multivariate analysis did not identify PNI as an independent prognostic factor for PFS. Furthermore, univariate analysis revealed that GPS, BMI, and PLR exhibited similar values for OS but not NLR and PNI. Patients with PNI =45 were predicted to have better OS than those with PNI <45 (OS: 23.4 and 13.9 months, respectively, p=0.0028). Multivariate analysis did not establish NLR as an independent prognostic factor for OS.Discussion/Conclusion: The PNI evidently predicted OS in NSCLC patients treated with Pemb-combination as first-line therapy, thereby validating its efficiency as a prognostic indicator of NSCLC.

引用

页码：30 / 42

页数：13

共 84 条

[1] Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer [J].

Bagley, Stephen J. ;

Kothari, Shawn ;

Aggarwal, Charu ;

Bauml, Joshua M. ;

Alley, Evan W. ;

Evans, Tracey L. ;

Kosteva, John A. ;

Ciunci, Christine A. ;

Gabriel, Peter E. ;

Thompson, Jeffrey C. ;

Stonehouse-Lee, Susan ;

Sherry, Victoria E. ;

Gilbert, Elizabeth ;

Eaby-Sandy, Beth ;

Mutale, Faith ;

DiLullo, Gloria ;

Cohen, Roger B. ;

Vachani, Anil ;

Langer, Corey J. .

LUNG CANCER, 2017, 106 :1-7

[2] Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab [J].

Capone, Mariaelena ;

Giannarelli, Diana ;

Mallardo, Domenico ;

Madonna, Gabriele ;

Festino, Lucia ;

Grimaldi, Antonio Maria ;

Vanella, Vito ;

Simeone, Ester ;

Paone, Miriam ;

Palmieri, Giuseppe ;

Cavalcanti, Ernesta ;

Caraco, Corrado ;

Ascierto, Paolo Antonio .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[3] Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014 [J].

Choi, Chang-Min ;

Kim, Ho Cheol ;

Jung, Chi Young ;

Cho, Deog Gon ;

Jeon, Jae Hyun ;

Lee, Jeong Eun ;

Ahn, Jin Seok ;

Kim, Seung Joon ;

Kim, Yeongdae ;

Choi, Yoo-Duk ;

Suh, Yang-Gun ;

Kim, Jung-Eun ;

Lee, Boram ;

Won, Young-Joo ;

Kim, Young-Chul .

CANCER RESEARCH AND TREATMENT, 2019, 51 (04) :1400-1410

[4] A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable [J].

Cortellini, Alessio ;

Bersanelli, Melissa ;

Buti, Sebastiano ;

Cannita, Katia ;

Santini, Daniele ;

Perrone, Fabiana ;

Giusti, Raffaele ;

Tiseo, Marcello ;

Michiara, Maria ;

Di Marino, Pietro ;

Tinari, Nicola ;

De Tursi, Michele ;

Zoratto, Federica ;

Veltri, Enzo ;

Marconcini, Riccardo ;

Malorgio, Francesco ;

Russano, Marco ;

Anesi, Cecilia ;

Zeppola, Tea ;

Filetti, Marco ;

Marchetti, Paolo ;

Botticelli, Andrea ;

Cappellini, Gian Carlo Antonini ;

De Galitiis, Federica ;

Vitale, Maria Giuseppa ;

Rastelli, Francesca ;

Pergolesi, Federica ;

Berardi, Rossana ;

Rinaldi, Silvia ;

Tudini, Marianna ;

Silva, Rosa Rita ;

Pireddu, Annagrazia ;

Atzori, Francesco ;

Chiari, Rita ;

Ricciuti, Biagio ;

De Giglio, Andrea ;

Iacono, Daniela ;

Gelibter, Alain ;

Occhipinti, Mario Alberto ;

Parisi, Alessandro ;

Porzio, Giampiero ;

Fargnoli, Maria Concetta ;

Ascierto, Paolo Antonio ;

Ficorella, Corrado ;

Natoli, Clara .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[5] Cancer-related inflammation and treatment effectiveness [J].

Diakos, Connie I. ;

Charles, Kellie A. ;

McMillan, Donald C. ;

Clarke, Stephen J. .

LANCET ONCOLOGY, 2014, 15 (11) :E493-E503

[6] The Prognostic Value of PLR in Lung Cancer, a Meta-analysis Based on Results from a Large Consecutive Cohort [J].

Ding, Nan ;

Pang, ZhaoFei ;

Shen, Hongchang ;

Ni, Yang ;

Du, Jiajun ;

Liu, Qi .

SCIENTIFIC REPORTS, 2016, 6

[7] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[8] Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms [J].

Elinav, Eran ;

Nowarski, Roni ;

Thaiss, Christoph A. ;

Hu, Bo ;

Jin, Chengcheng ;

Flavell, Richard A. .

NATURE REVIEWS CANCER, 2013, 13 (11) :759-771

[9] Non-Small Cell Lung Cancer, Version 3.2022 [J].

Ettinger, David S. ;

Wood, Douglas E. ;

Aisner, Dara L. ;

Akerley, Wallace ;

Bauman, Jessica R. ;

Bharat, Ankit ;

Bruno, Debora S. ;

Chang, Joe Y. ;

Chirieac, Lucian R. ;

D'Amico, Thomas A. ;

DeCamp, Malcolm ;

Dilling, Thomas J. ;

Dowell, Jonathan ;

Gettinger, Scott ;

Grotz, Travis E. ;

Gubens, Matthew A. ;

Hegde, Aparna ;

Lackner, Rudy P. ;

Lanuti, Michael ;

Lin, Jules ;

Loo, Billy W. ;

Lovly, Christine M. ;

Maldonado, Fabien ;

Massarelli, Erminia ;

Morgensztern, Daniel ;

Ng, Thomas ;

Otterson, Gregory A. ;

Pacheco, Jose M. ;

Patel, Sandip P. ;

Riely, Gregory J. ;

Riess, Jonathan ;

Schild, Steven E. ;

Shapiro, Theresa A. ;

Singh, Aditi P. ;

Stevenson, James ;

Tam, Alda ;

Tanvetyanon, Tawee ;

Yanagawa, Jane ;

Yang, Stephen C. ;

Yau, Edwin ;

Gregory, Kristina ;

Hughes, Miranda .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (05) :497-530

[10] Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor [J].

Fang, Qiyu ;

Yu, Jia ;

Luo, Jie ;

Deng, Qinfang ;

Chen, Bin ;

He, Yayi ;

Zhang, Jie ;

Zhou, Caicun .

CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16

← 1 2 3 4 5 6 7 8 9 →